358 related articles for article (PubMed ID: 26667491)
1. Eradication of Large Solid Tumors by Gene Therapy with a T-Cell Receptor Targeting a Single Cancer-Specific Point Mutation.
Leisegang M; Engels B; Schreiber K; Yew PY; Kiyotani K; Idel C; Arina A; Duraiswamy J; Weichselbaum RR; Uckert W; Nakamura Y; Schreiber H
Clin Cancer Res; 2016 Jun; 22(11):2734-43. PubMed ID: 26667491
[TBL] [Abstract][Full Text] [Related]
2. Rapid Construction of Antitumor T-cell Receptor Vectors from Frozen Tumors for Engineered T-cell Therapy.
Tsuji T; Yoneda A; Matsuzaki J; Miliotto A; Ryan C; Koya RC; Odunsi K
Cancer Immunol Res; 2018 May; 6(5):594-604. PubMed ID: 29588318
[TBL] [Abstract][Full Text] [Related]
3. One CD4+TCR and One CD8+TCR Targeting Autochthonous Neoantigens Are Essential and Sufficient for Tumor Eradication.
Wolf SP; Anastasopoulou V; Drousch K; Diehl MI; Engels B; Yew PY; Kiyotani K; Nakamura Y; Schreiber K; Schreiber H; Leisegang M
Clin Cancer Res; 2024 Apr; 30(8):1642-1654. PubMed ID: 38190111
[TBL] [Abstract][Full Text] [Related]
4. Targeting cancer-specific mutations by T cell receptor gene therapy.
Blankenstein T; Leisegang M; Uckert W; Schreiber H
Curr Opin Immunol; 2015 Apr; 33():112-9. PubMed ID: 25728991
[TBL] [Abstract][Full Text] [Related]
5. Identification of an HLA-A*11:01-restricted neoepitope of mutant PIK3CA and its specific T cell receptors for cancer immunotherapy targeting hotspot driver mutations.
Shen M; Chen S; Han X; Hao Y; Wang J; Li L; Chen T; Wang B; Zou L; Zhang T; Zhang W; Han X; Wang W; Yu H; Li K; Liu S; Jin A
Cancer Immunol Immunother; 2024 Jun; 73(8):150. PubMed ID: 38832948
[TBL] [Abstract][Full Text] [Related]
6. IND-Enabling Studies for a Clinical Trial to Genetically Program a Persistent Cancer-Targeted Immune System.
Puig-Saus C; Parisi G; Garcia-Diaz A; Krystofinski PE; Sandoval S; Zhang R; Champhekar AS; McCabe J; Cheung-Lau GC; Truong NA; Vega-Crespo A; Komenan MDS; Pang J; Macabali MH; Saco JD; Goodwin JL; Bolon B; Seet CS; Montel-Hagen A; Crooks GM; Hollis RP; Campo-Fernandez B; Bischof D; Cornetta K; Gschweng EH; Adelson C; Nguyen A; Yang L; Witte ON; Baltimore D; Comin-Anduix B; Kohn DB; Wang X; Cabrera P; Kaplan-Lefko PJ; Berent-Maoz B; Ribas A
Clin Cancer Res; 2019 Feb; 25(3):1000-1011. PubMed ID: 30409823
[TBL] [Abstract][Full Text] [Related]
7. In vivo programming of tumor antigen-specific T lymphocytes from pluripotent stem cells to promote cancer immunosurveillance.
Lei F; Zhao B; Haque R; Xiong X; Budgeon L; Christensen ND; Wu Y; Song J
Cancer Res; 2011 Jul; 71(14):4742-7. PubMed ID: 21628492
[TBL] [Abstract][Full Text] [Related]
8. Cancer immunotherapy with lymphocytes genetically engineered with T cell receptors for solid cancers.
Chen L; Qiao D; Wang J; Tian G; Wang M
Immunol Lett; 2019 Dec; 216():51-62. PubMed ID: 31597088
[TBL] [Abstract][Full Text] [Related]
9. Successful elimination of large established tumors and avoidance of antigen-loss variants by aggressive adoptive T cell immunotherapy.
Matsui K; O'Mara LA; Allen PM
Int Immunol; 2003 Jul; 15(7):797-805. PubMed ID: 12807818
[TBL] [Abstract][Full Text] [Related]
10. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
[No Abstract] [Full Text] [Related]
11. Permissive expansion and homing of adoptively transferred T cells in tumor-bearing hosts.
Perez C; Jukica A; Listopad JJ; Anders K; Kühl AA; Loddenkemper C; Blankenstein T; Charo J
Int J Cancer; 2015 Jul; 137(2):359-71. PubMed ID: 25530110
[TBL] [Abstract][Full Text] [Related]
12. Re-adapting T cells for cancer therapy: from mouse models to clinical trials.
Stromnes IM; Schmitt TM; Chapuis AG; Hingorani SR; Greenberg PD
Immunol Rev; 2014 Jan; 257(1):145-64. PubMed ID: 24329795
[TBL] [Abstract][Full Text] [Related]
13. Accumulation of CD8+ T cells in advanced-stage tumors and delay of disease progression following secondary immunization against an immunorecessive epitope.
Ryan CM; Schell TD
J Immunol; 2006 Jul; 177(1):255-67. PubMed ID: 16785521
[TBL] [Abstract][Full Text] [Related]
14. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
[TBL] [Abstract][Full Text] [Related]
15. TCR validation toward gene therapy for cancer.
Green EW; Bunse L; Bozza M; Sanghvi K; Platten M
Methods Enzymol; 2019; 629():419-441. PubMed ID: 31727252
[TBL] [Abstract][Full Text] [Related]
16. High-throughput discovery of cancer-targeting TCRs.
Bunse L; Green EW; Platten M
Methods Enzymol; 2019; 629():401-417. PubMed ID: 31727251
[TBL] [Abstract][Full Text] [Related]
17. Enhancing antitumor response by efficiently generating large-scale TCR-T cells targeting a single epitope across multiple cancer antigens.
Amissah OB; Basnet R; Chen W; Habimana JD; Baiden BE; Owusu OA; Saeed BJ; Li Z
Cell Immunol; 2024; 399-400():104827. PubMed ID: 38733699
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3.
Lu YC; Parker LL; Lu T; Zheng Z; Toomey MA; White DE; Yao X; Li YF; Robbins PF; Feldman SA; van der Bruggen P; Klebanoff CA; Goff SL; Sherry RM; Kammula US; Yang JC; Rosenberg SA
J Clin Oncol; 2017 Oct; 35(29):3322-3329. PubMed ID: 28809608
[TBL] [Abstract][Full Text] [Related]
19. Transfer of Allogeneic CD4+ T Cells Rescues CD8+ T Cells in Anti-PD-L1-Resistant Tumors Leading to Tumor Eradication.
Arina A; Karrison T; Galka E; Schreiber K; Weichselbaum RR; Schreiber H
Cancer Immunol Res; 2017 Feb; 5(2):127-136. PubMed ID: 28077434
[TBL] [Abstract][Full Text] [Related]
20. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer.
Stanislawski T; Voss RH; Lotz C; Sadovnikova E; Willemsen RA; Kuball J; Ruppert T; Bolhuis RL; Melief CJ; Huber C; Stauss HJ; Theobald M
Nat Immunol; 2001 Oct; 2(10):962-70. PubMed ID: 11577350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
